Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas

NCT00004057 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: L-778,123
DRUG: paclitaxel

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]